Compound stypticum

A drug and compound technology, applied in the field of medicine, can solve problems such as adverse immune response, limited dosage, glomerular damage, etc.

Active Publication Date: 2009-12-30
GRAND LIFE SCI (LIAONING) CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In fact, as a large-molecular-weight protein drug, it is easy to cause adverse immune responses to the human body, such as: fever response, production of antibodies, formation of immune complexes with large molecular weight, and certain damage to glomeruli, thus limiting its use. dose

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound stypticum
  • Compound stypticum
  • Compound stypticum

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Prescription: thrombin-like enzyme 50u

[0021] IL-11 500mg

[0022] Glycine 1000mg

[0023] Mannitol 4000mg

[0024]

[0025] Add water for injection to 200ml

[0026] The thrombin in the prescription is the thrombin-like batroxobin contained in the venom of Agkistrodon lancehead, and rhIL-11 is recombinant human interleukin-11.

[0027] Preparation process: Weigh the prescription amount of raw materials and auxiliary materials in a clean room, put them in a sterilized container, add 200ml of sterilized water for injection, stir to dissolve, add 1% of the prescription amount of activated carbon for needles, stir well, and let stand for 30min , filtered through a 0.8 μm microporous membrane filter, and then filtered through a 0.22 μm microporous membrane sterilizer, and then packed in sterilized vials. Pre-freeze at -30°C-40°C for 2-3 hours, sublimate and dry at -20°C for 9 hours, dry at 30°C for ...

Embodiment 2

[0031] Prescription: thrombin-like enzyme 50u

[0032] IL-11 500mg

[0033] Glycine 1000mg

[0034] Mannitol 4000mg

[0035]

[0036] Add water for injection to 200ml

[0037] The thrombin-like enzyme in the prescription is the thrombin-like enzyme contained in the venom of Agkistrodon halys, and the IL-11 is recombinant human interleukin-11.

[0038] Preparation process: Weigh the prescription amount of raw materials and auxiliary materials in a clean room, put them in a sterilized container, add 200ml of sterilized water for injection, stir to dissolve, add 1% of the prescription amount of activated carbon for needles, stir well, and let stand for 30min , filtered through a 0.8 μm microporous membrane filter, and then filtered through a 0.22 μm microporous membrane sterilizer, and then packed in sterilized vials. Pre-freeze at -30°C-40°C for 2-3 hours, sublimate and dry at -20°C for 9 hours, dry at 30°C fo...

Embodiment 3

[0042] Prescription: thrombin-like enzyme 50u

[0043] IL-11 500mg

[0044] Glycine 1000mg

[0045] Mannitol 4000mg

[0046]

[0047] Add water for injection to 200ml

[0048] The thrombin-like enzyme in the prescription is the thrombin-like enzyme contained in the venom of Agkistrodon akistrodon, and the IL-11 is recombinant human interleukin-11.

[0049] Preparation process: Weigh the prescription amount of raw materials and auxiliary materials in a clean room, put them in a sterilized container, add 200ml of sterilized water for injection, stir to dissolve, add 1% of the prescription amount of activated carbon for needles, stir well, and let stand for 30min , filtered through a 0.8 μm microporous membrane filter, and then filtered through a 0.22 μm microporous membrane sterilizer, and then packed in sterilized vials. Pre-freeze at -30°C-40°C for 2-3 hours, sublimate and dry at -20°C for 9 hours, dry a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A compound medicine for arresting bleeding is characterized in that the compound medicine is a mixture of a batroxobin and an interleukin-11; the clinical dosage of the batroxobin is 0.01-10u and that of IL-11 is 0.06-50mg; the batroxobin is the batroxobin from snake venom of Brazilian spearhead adder, white-eyebrow adder or acutus adder, or the batroxobin from recombinant Brazilian spearhead adder, white-eyebrow adder or acutus adder obtained by genetic engineering; the interleukin-11 is produced by human bone-marrow stromal cells (fibroblasts) and interstitial cells, or the recombinant IL-11 by genetic engineering. The medicine for arresting bleeding can not only ensure the curative effect but also decrease the amount of protease so as to reduce the rate of adverse immune response.

Description

Technical field: [0001] The invention relates to the technical field of medicine, in particular to a compound hemostatic drug containing two active components of thrombin-like enzyme and IL-11 and a preparation process thereof. Background technique: [0002] In 1963, the Austrian scholar Von Klobusitzky isolated various coagulation components from the venom of the Brazilian spearhead viper (Bothrops atrox) for the first time, and found that they functioned at different levels of coagulation. The first isolated and purified coagulation component is Batroxobin, which is a serine proteolytic enzyme (Thrombin-LikeEnzyme-like thrombin), also known as Batroxobin (Stocker, K., & Egberg, n., 1973, Thromb. Diath. Haemorrh. 1, 361; Stocker, K., & Barlow, G.H., 1976, Method Enzymol. 45, 214; Holleman, W.H., & Weiss, L.J., 1976, J. Biol. Chem. 251.1663). Batroxobin digests fibrin peptide A in mammalian plasma fibrinogen to convert it into fibrin, so it can cause the aggregation of plas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/57A61K38/20A61P7/04
Inventor 薛百忠王宏英薛雁李英苏珊高欣沈文彧吴琼徐梅邹晓坡
Owner GRAND LIFE SCI (LIAONING) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap